The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology
Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.
Our CEO was recently asked how far away is fully computational drug discovery and development. This isn’t an easy question to answer and Andrew doesn’t provide an exact date. However, he does provide interesting insight into the progress we’ve made and the challenges ahead.